Shares of Berkeley, Calif., biotech Xoma ( XOMA) fell sharply in the premarket session after phase II tests studying Raptiva as a rheumatoid arthritis treatment were ended by it and Genentech ( DNA).

The studies were called off after showing Raptiva was having no overall clinical benefit in arthritis patients receiving it. The treatment continues to be evaluated by the FDA as a treatment for psoriasis.

Xoma was recently off 55 cents, or 10%, to $4.90 on Instinet.

More from Stocks

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

Novo Nordisk Stock Rises 4% Over 2 Sessions

Novo Nordisk Stock Rises 4% Over 2 Sessions

Stock Market Just Took Another Beating -- Here's What You Need to Know

Stock Market Just Took Another Beating -- Here's What You Need to Know

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

Daimler's Profit Warning Should Terrify Traders Before Earnings Season Begins

Daimler's Profit Warning Should Terrify Traders Before Earnings Season Begins